Quantbot Technologies LP Has $574,000 Stock Position in United Therapeutics Corporation $UTHR

Key Points

• Quantbot Technologies LP significantly increased its holdings in United Therapeutics Corporation by 5,072.2%, acquiring 1,862 shares valued at $574,000 by the end of the first quarter.
• Other institutional investors, including Korea Investment CORP and Qtron Investments LLC, also boosted their stakes in United Therapeutics, reflecting a strong interest in the company among hedge funds.
• United Therapeutics' stock experienced a 2.2% decline in value, with a recent earnings report showing a miss on EPS estimates, posting $6.41 against the consensus of $6.80.

Quantbot Technologies LP boosted its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 5,072.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,862 shares of the biotechnology company's stock after purchasing an additional 1,826 shares during the period. Quantbot Technologies LP's holdings in United Therapeutics were worth $574,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Dunhill Financial LLC lifted its position in shares of United Therapeutics by 100.0% in the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 50 shares in the last quarter. Sound Income Strategies LLC purchased a new stake in shares of United Therapeutics in the 1st quarter valued at approximately $49,000. State of Wyoming purchased a new stake in shares of United Therapeutics in the 4th quarter valued at approximately $62,000. Brooklyn Investment Group lifted its position in shares of United Therapeutics by 103.2% in the 1st quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company's stock valued at $59,000 after acquiring an additional 98 shares in the last quarter. Finally, Curat Global LLC purchased a new stake in shares of United Therapeutics in the 1st quarter valued at approximately $63,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at United Therapeutics

In other news, Director Nilda Mesa sold 645 shares of the stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total transaction of $187,043.55. Following the transaction, the director owned 4,883 shares in the company, valued at $1,416,021.17. This represents a 11.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Richard Giltner sold 3,036 shares of the stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total transaction of $879,225.60. Following the transaction, the director owned 19,384 shares in the company, valued at approximately $5,613,606.40. This trade represents a 13.54% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 81,681 shares of company stock worth $24,537,839. Company insiders own 10.30% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on UTHR shares. UBS Group upped their price target on shares of United Therapeutics from $385.00 to $415.00 and gave the company a "buy" rating in a research report on Wednesday, August 13th. HC Wainwright set a $400.00 price target on shares of United Therapeutics and gave the company a "buy" rating in a research report on Thursday, July 31st. Wells Fargo & Company reduced their price target on shares of United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating for the company in a research report on Thursday, July 31st. Cantor Fitzgerald restated an "overweight" rating on shares of United Therapeutics in a research report on Thursday, August 14th. Finally, JPMorgan Chase & Co. reduced their price target on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research report on Tuesday, July 8th. Nine investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $382.00.

United Therapeutics Trading Down 0.8%

UTHR stock traded down $2.48 during midday trading on Friday, reaching $304.76. The company had a trading volume of 418,774 shares, compared to its average volume of 695,087. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $417.82. The company has a market capitalization of $13.75 billion, a P/E ratio of 11.90, a PEG ratio of 4.62 and a beta of 0.62. The company has a 50 day moving average of $298.66 and a two-hundred day moving average of $305.23.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company had revenue of $798.60 million during the quarter, compared to analysts' expectations of $802.13 million. During the same quarter in the previous year, the company earned $5.85 EPS. The firm's quarterly revenue was up 11.7% compared to the same quarter last year. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.